Drug name - Xiidra

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7928122 NOVARTIS Modulators of cellular adhesion
Nov, 2024

(1 year, 10 months from now)

US7745460 NOVARTIS Modulators of cellular adhesion
Nov, 2024

(1 year, 10 months from now)

US7314938 NOVARTIS Modulators of cellular adhesion
Mar, 2025

(2 years from now)

US8084047 NOVARTIS Compositions and methods for treatment of eye disorders
May, 2026

(3 years from now)

US9890141 NOVARTIS Crystalline pharmaceutical and methods of preparation and use thereof
Oct, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7790743 NOVARTIS Modulators of cellular adhesion
Nov, 2024

(1 year, 10 months from now)

US9216174 NOVARTIS Modulators of cellular adhesion
Nov, 2024

(1 year, 10 months from now)

US10124000 NOVARTIS Modulators of cellular adhesion
Nov, 2024

(1 year, 10 months from now)

US8592450 NOVARTIS Compositions and methods for treatment of eye disorders
May, 2026

(3 years from now)

US9447077 NOVARTIS Crystalline pharmaceutical and methods of preparation and use thereof
Apr, 2029

(6 years from now)

US8367701 NOVARTIS Crystalline pharmaceutical and methods of preparation and use thereof
Apr, 2029

(6 years from now)

US8168655 NOVARTIS Compositions and methods for treatment of eye disorders
May, 2029

(6 years from now)

US9353088 NOVARTIS Crystalline pharmaceutical and methods of preparation and use thereof
Oct, 2030

(7 years from now)

US8927574 NOVARTIS Crystalline pharmaceutical and methods of preparation and use thereof
Nov, 2030

(7 years from now)

US9085553 NOVARTIS LFA-1 inhibitor and methods of preparation and polymorph thereof
Jul, 2033

(10 years from now)

US11058677 NOVARTIS LFA-1 inhibitor formulations
Dec, 2033

(11 years from now)

Drugs and Companies using LIFITEGRAST ingredient

Market Authorisation Date: 11 July, 2016

Treatment: Treatment of signs and symptoms of dry eye disease (ded); Treatment of the signs and symptoms of dry eye disease (ded)

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
5% SOLUTION/DROPS;OPHTHALMIC Prescription

availability in other generic markets.

Click on the highlighted region to filter.